HIV阳性供肾移植给HIV阳性受者的感染分析
该研究为HOPE in Action KT试验的二次分析,比较99例HIV D+/R+与99例HIV D-/R+肾移植受者术后24个月内首次临床相关感染的时间。HIV D+/R+组24个月累积感染发生率为73.8%,HIV D-/R+组为64.7%,校正后风险比为1.44,但住院相关感染风险无显著差异。
要点
- HIV D+/R+肾移植后24个月临床相关感染累积发生率高于HIV D-/R+,aHR为1.44。
- 住院相关感染风险在两组间无显著差异,aHR为1.21。
- 感染数量、感染死亡、持续时间和部位无显著差异,病毒性感染在HIV D+/R+组略多。
核心结论
- HIV D+/R+肾移植术后24个月内首次临床相关感染风险显著高于HIV D-/R+,但住院相关感染风险无显著差异。
研究设计与样本
- HOPE in Action KT研究(NCT02602262)的二次分析,比较99例HIV D+/R+与99例HIV D-/R+肾移植受者术后24个月内首次临床相关感染时间。
主要发现
- HIV D+/R+组24个月临床相关感染累积发生率为73.8%(95%CI:63.1%-81.2%),HIV D-/R+组为64.7%(95%CI:53.0%-73.4%)。
- HIV D+/R+ vs HIV D-/R+首次临床相关感染的aHR为1.44(95%CI:1.01-2.04)。
- 感染数量、感染死亡、持续时间或部位无显著差异,病毒性感染在HIV D+/R+组为40% vs 35%。
临床怎么用
- HIV D+/R+肾移植后应关注临床相关感染风险,尤其是病毒性感染,但住院相关感染风险与HIV D-/R+相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Kidney transplantation (KT) from donors with human immunodeficiency virus (HIV-1) to recipients with HIV (HIV D+/R+) is noninferior to KT from donors without HIV (HIV D-/R+) with regard to safety. However, there may be differences in posttransplant infections. METHODS: We performed a secondary analysis of the HOPE in Action KT Study (NCT02602262) comparing the time to first clinically relevant infection within 24 months posttransplantation in 99 HIV D+/R+ versus 99 HIV D-/R+. Secondary outcomes included incidence rates, infection-related death, and timing of clinically relevant infection, each stratified by donor HIV status. RESULTS: The cumulative incidence of a clinically relevant infection at 24 months posttransplantation was 73.8% (95% confidence interval [CI]: 63.1%-81.2%) for HIV D+/R+ versus 64.7% (95% CI: 53.0%-73.4%) for HIV D-/R+. Comparing time to first clinically relevant infection in HIV D+/R+ versus HIV D-/R+, the adjusted hazard ratio (aHR) was 1.44 (95% CI: 1.01-2.04) at 24 months posttransplantation; for infections associated with hospitalization, the aHR was not significantly higher (1.21 [95% CI: .78-1.86). There were no significant differences in the number of infections, death from infection, duration, or site of infection between HIV D+/R+ versus HIV D-/R+, though viral infections were numerically more common in HIV D+/R+ (40% vs 35%). CONCLUSIONS: Although there was a statistically significant association between receipt of a kidney from a donor with HIV and time to first clinically relevant infection in the 24 months posttransplantation, there were no differences in infections associated with hospitalization. These data are overall reassuring as this emerging practice expands into clinical care. Clinical Trials Registration. NCT02602262.
引用
- Arant EC, Davy-Mendez T, Liang T, et al. Infections After Kidney Transplantation From Donors With HIV to Recipients With HIV. Clin Infect Dis. 2026. PMID: 41524130. doi:10.1093/cid/ciaf656
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。